Edition:
United States

Alchemia Ltd (ACL.AX)

ACL.AX on Australia Stock Exchange

0.01AUD
28 Mar 2019
Change (% chg)

-- (--)
Prev Close
$0.01
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
$0.02
52-wk Low
$0.01

Summary

Name Age Since Current Position

Cameron Petricevic

2019 Non-Executive Chairman of the Board

Melanie Leydin

2019 Chief Financial Officer, Company Secretary, Director

Tracey Brown

2013 Chief Scientific Officer, Vice President - Oncology

Michael West

2005 Vice President - Intellectual Property and Technology Transfer

Goslik Schepers

2009 Vice President - Business Development

Imran Ahamed

2013 Group Financial Controller

Wim Meutermans

2000 Chief Scientific Officer - Audeo Discovery

Michael Sapountzis

2019 Joint Company Secretary

Lynden Polonsky

2019 Director

Biographies

Name Description

Cameron Petricevic

Mr. Cameron Petricevic is Non-Executive Chairman of the Board of the company. He has over 15 years’ experience within the finance industry primarily across the areas of investments, valuations and corporate finance. He joined Kentgrove Capital in late 2015 as a Partner focusing on investments and equity capital markets transactions. Previously, he spent almost 5 years at Acorn Capital as Portfolio Manager across private and public investments. Most notably prior to that, he spent time at AXA Asia Pacific Holdings as a Corporate Finance (Mergers/Acquisitions) manager. Cameron is also the founder and a Non-Executive Director of CommsChoice Group (ASX: CCG).

Melanie Leydin

Ms. Melanie Jaye Leydin is Chief Financial Officer, Company Secretary, Director of the Company. Ms Leydin is a Chartered Accountant, Registered Company Auditor and is Alchemia’s Chief Financial Officer and Company Secretary. Ms Leydin’s experience in public company responsibilities includes ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, reorganisation of companies and shareholder relations. Ms Leydin has 25 years’ experience in the accounting profession, 13 years’ experience as a company secretary and is a director and company secretary for a number of entities listed on the Australian Securities Exchange.

Tracey Brown

Ms. Tracey J. Brown, Ph.D., is Chief Scientific Officer, Vice President - Oncology of Alchemia Ltd. She joined Alchemia in 2006 as a result of the acquisition of Meditech. She is responsible for the evaluation of lead compounds from both Alchemia’s discovery and HyACT programs where her primary role is to take the potential therapeutics into both non-clinical and clinical development. Over the last 28 years, Tracey has researched the biochemistry and therapeutic applications of carbohydrates, where this experience culminated in the invention of the HyACT platform and the development of three drugs from conception through to clinical evaluation. During her career, Tracey has gained international experience in managing both academic and commercial scientific teams and as the Chief Scientific Officer, Tracey directs Alchemia’s team at Monash University where she holds an adjunct position as an Associate Professor in the Department of Biochemistry and Molecular Biology.

Michael West

Mr. Michael (Mike) L. West, Ph.D., is Vice President - Intellectual Property and Technology Transfer of Alchemia Ltd since 2005. He joined Alchemia in December 1997 as its first employee and has held positions in research and development and is currently the Vice President of Intellectual Property and Technology Transfer. In addition to his role in Intellectual Property and Technology Transfer, Michael is responsible for the manufacturing and scale up activities of Alchemia products and intermediates. Michael has spent over 12 years in collaboration with the DOW Chemical Company and Dr Reddy’s Laboratories on the industrial development of fondaparinux sodium. He has undertaken the scale up of a number of VAST compounds, and is responsible for the manufacturing activities for HA-Irinotecan. Michael holds a PhD in Chemistry and a Masters in Industrial Property. Michael has industrial post-doctoral experience at GlaxoSmithKline US, as well as in academia where he worked as a senior postdoctoral fellow and CARGS fellow at the Centre for Drug Design and Development at the University of Queensland. Michael is a co-inventor on 25 patent families containing 34 issued patents and more than 32 applications. Michael has also co-authored a number of peer reviewed publications. Michael is a registered Australian Patent and Trade Mark attorney.

Goslik Schepers

Mr. Goslik Schepers is Vice President - Business Development of Alchemia Ltd. He has served as Vice President of Business Development since May 2009 and has over 15 years’ experience in commercialisation and business development. Prior to this appointment, Goslik served as Business Development Manager for VASTox plc (now Summit plc) where he helped to establish and grow the revenue base for Summit. Prior to Summit, Goslik worked in technology transfer for Oxford University and The University of Queensland. Goslik graduated from the University of Queensland with a PhD in molecular and developmental biology.

Imran Ahamed

Mr. Imran Ahamed is Group Financial Controller of Alchemia Ltd. He was appointed to the position of Group Financial Controller in February 2013, following one year as Alchemia Oncology’s Financial Controller. He brings over 20 years of accounting and finance experience to the role, having worked in senior finance positions in investment banking, manufacturing, retail and wholesale sectors in Asia, Southern Africa, the Middle East and Australia. Imran’s expertise includes: strong technical skills in financial and management accounting, statutory reporting, budgeting and control, systems and procedures and financial analysis. He has also been involved in corporate finance transactions which include IPOs, M&As, capital restructuring and feasibility studies.

Wim Meutermans

Dr. Wim Meutermans, Ph.D., is Chief Scientific Officer - Audeo Discovery of Alchemia Ltd. He joined Alchemia in April 2000 and as Chief Scientific Officer – Audeo is responsible for all the small molecule drug discovery projects within Alchemia. Wim has over 20 years’ experience in all non-clinical aspects of drug discovery and managing multiple discovery programs in diverse therapeutic indications, including Alchemia’s ACL16907 which was taken to full preclinical assessment. Wim is also one of the key inventors of the VAST small molecule discovery platform. He is responsible for managing Alchemia’s small molecule drug discovery efforts in the field of oncology, respiratory disease, metabolic disorders and pain. He is co-inventor on 12 patents and has published extensively. Prior to his appointment with Alchemia he was employed at the Centre for Drug Design as Senior Research Officer to manage academic and industry sponsored drug discovery projects. Wim obtained a PhD from the Katholieke Universiteit Leuven in Belgium.

Michael Sapountzis

Lynden Polonsky

Mr. Lynden Polonsky is Director of the Company. Mr Polonsky has over 15 years’ experience within the finance industry. Mr Polonsky has provided merger, acquisition, divestment and capital markets advice across a range of industries and sectors including natural resources, infrastructure, renewable energy, healthcare and retail. Mr Polonsky has worked for leading global investment banks and was a founding partner at a boutique corporate advisory firm.

Basic Compensation